ARTICLE | Company News
QLT's Visudyne sNDA gets priority review
August 29, 2000 7:00 AM UTC
QLTI and partner Ciba Vision will receive priority FDA review for an sNDA for QLTI's Visudyne photodynamic therapy to treat patients with choroidal neovascularization (CNV) caused by macular diseases ...